Washington D.C. – Robert F. Kennedy Jr., serving as the Secretary of Health and Human Services (HHS), announced a controversial policy on Wednesday that would significantly broaden patient access to unapproved peptide injections. These compounds, popularized by online influencers, would bypass standard Food and Drug Administration (FDA) safeguards typically required for drug approval, a move that has ignited serious concerns among drug safety experts and former regulatory officials.
Under the new policy, Secretary Kennedy has invoked “enforcement discretion,” effectively allowing companies to produce and distribute these unproven injections without undergoing the rigorous review processes usually mandated by the FDA. This typically includes comprehensive tests to determine a compound’s efficacy against a placebo, as well as crucial safety assessments for potential adverse effects such as carcinogenicity or birth defects.
Secretary Kennedy, who has publicly stated his personal use and perceived benefits from peptides, has been a vocal proponent of this change. Earlier this year, he indicated on various podcasts that the FDA would soon relax restrictions on the widespread use of these substances, setting the stage for Wednesday’s announcement.
The decision appears to be a unilateral action by the Secretary, a highly unusual development in federal drug policy. The document outlining the new policy, posted on the HHS website, explicitly frames the decision as Mr. Kennedy’s alone. Notably, FDA scientists had previously advised against widespread use of these particular peptides, and agency representatives were reportedly absent from at least one meeting held on Tuesday to finalize the policy, suggesting a significant divergence in approach between the HHS leadership and the FDA’s scientific counsel.
An official statement from the HHS document asserted, “The secretary has determined that the policy advances patient choice and freedom while appropriately protecting patient safety.” Emily Hilliard, a spokeswoman for the Department of Health and Human Services, elaborated on the policy’s intent, stating it aims to “confront the risks of black-market peptides.” She added that the new framework would require “patient-specific prescriptions, traceable ingredients, quality testing and safety reporting to hold compounders accountable and give patients an alternative to unregulated sellers.” However, Hilliard also clarified a crucial point: “The policy does not grant F.D.A. approval or establish clinical safety and effectiveness.”
Peptides are naturally occurring short chains of amino acids that serve as fundamental biological messengers, instructing the body’s cells to perform various functions. The FDA has approved numerous peptide compounds for medical use, such as insulin for diabetes management and glucagon-like peptide-1 (GLP-1) drugs, which are prescribed for diabetes and widely utilized for weight loss. These approved peptides have undergone extensive clinical trials to establish their safety and efficacy.
In contrast, the six specific peptides that Secretary Kennedy’s policy now permits for wider access lack this crucial scientific evidence of efficacy or safety from comprehensive, regulated studies. These include epitalon, often marketed with claims of promoting longevity, and BPC-157, sometimes referred to as the “wolverine” peptide, which is purportedly used for muscle repair. Unlike the well-researched GLP-1 drugs, no major pharmaceutical company has invested in the costly and stringent regulatory studies required for these compounds to receive FDA approval.
The allowance of widespread use for these unapproved peptides aligns with the “medical freedom” philosophy often espoused by some of Secretary Kennedy’s supporters. This viewpoint typically advocates for the right to choose treatments with limited scientific backing and often expresses skepticism towards widely studied public health interventions, such as vaccines.
While the new policy introduces certain criteria intended to offer public protections, their effectiveness is a point of contention. These criteria include requiring peptides to be manufactured at an FDA-registered facility, though this step primarily involves a manufacturer notifying the agency of its address rather than undergoing a substantive review. The policy also mandates adverse event reporting to the FDA and product labels that specify the active ingredient, strength, and a unique identifier for the manufacturing facility. These measures are designed to increase transparency and accountability within the new framework.
The compounded pharmacies responsible for blending these drugs are typically not household names but often collaborate with telehealth companies, some of which, like Hims & Hers and Noom, have expressed interest in dispensing these peptides. This potentially broadens the reach of these unapproved treatments significantly.
Dr. Janet Woodcock, who retired in 2024 after four decades in drug oversight at the FDA, sharply criticized the policy. She suggested that the move represents a regression to a time akin to “folk medicine endorsed by word of mouth,” which historically led to patient harm and necessitated the establishment and strengthening of the FDA. “It does undermine the idea that you would test drugs for safety and effectiveness before they were widely made available,” Dr. Woodcock stated, highlighting the foundational principle of modern drug regulation.
She further emphasized that without fundamental agency safeguards, these unapproved injections would lack the critical safety reviews that, for example, identified the devastating birth defects caused by thalidomide in Europe, preventing its approval as a morning sickness remedy in the United States thanks to a vigilant FDA reviewer.
The official policy document also asserts that Secretary Kennedy “has determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to U.S. patients.” This suggests the policy is partly intended to channel a currently unregulated market into a more observable, albeit less stringently vetted, domestic framework.
Earlier this year, the FDA initiated a process to potentially add certain peptides to a list of products that could be compounded by bespoke pharmacies for individual patient needs, a different pathway than full FDA approval. In July, a compounding committee convened to consider adding seven peptides to this list. During the hearing, FDA officials and patient safety advocates voiced significant concerns regarding the scarcity of fundamental information about these peptides, including their potential impacts on the immune system or their capacity to fuel tumor growth. Agency scientists formally recommended against adding these peptides to the list.
Conversely, other participants at the hearings testified about their positive personal experiences with peptides and underscored the inherent risks associated with dispensing any drug, whether approved or not. The committee, whose membership Mr. Kennedy’s department had curated to include a majority of individuals who prescribed peptides or worked in drug compounding, ultimately voted in favor of adding six of the compounds to the list. However, the FDA did not proceed with this step.
Dr. Woodcock characterized the decision to implement “enforcement discretion” as simply “a policy of looking the other way.” Despite some panelists at the July meeting raising concerns about “bad actors” prescribing unsafe peptides, it remains unclear whether the new policy will effectively curtail the operations of truly unregulated, illicit markets.
John Hertig, chairman of the Collaborative for Evidence-Based Medicines, expressed concern that the policy sends a misleading signal to the public. “I think what it translates to for the average consumer and someone looking for these peptides is there’s been a tacit recommendation from the F.D.A. and that it’s OK,” Hertig stated. He added, “When really there hasn’t been the diligence and the review and the scientific rigor that we deserve as the American public, in terms of what we ingest or inject.”
The peptides reviewed by the FDA panel earlier this summer are promoted for a diverse array of conditions. BPC-157, a particularly popular compound, is also marketed for joint healing. Semax is purported to address mental health and neurological conditions such as migraines, anxiety, and Parkinson’s disease. However, there is minimal research, especially in human subjects, to substantiate these extensive claims. Critics are concerned that individuals may opt for these unproven therapies, potentially delaying or forgoing FDA-approved medications that possess established safety and efficacy profiles.
Several of these peptides also purportedly target fundamental biological processes, which could lead to unforeseen and potentially dangerous side effects. Epitalon, for instance, is promoted as a longevity peptide due to its reported ability to lengthen telomeres—the protective caps on the ends of chromosomes that naturally shorten with age and are linked to cellular aging. However, unusually long telomeres have also been associated with an increased risk of cancer, raising concerns about epitalon’s potential carcinogenic effects.
Other peptides permitted under the new policy include KPV, often formulated as a cream or gel for wound healing and inflammatory skin conditions. MOTS-c, derived from mitochondrial DNA, is suggested to play a role in cellular metabolism, though human data supporting this claim is absent. TB-500, another peptide, was originally developed as a veterinary drug to enhance performance in racing greyhounds and horses, highlighting its non-human origin and lack of human safety data.
Dana G. Smith contributed to this report.
Why This Matters
The decision by Health and Human Services Secretary Robert F. Kennedy Jr. to allow widespread access to unapproved peptide injections carries significant implications for public health, the future of pharmaceutical regulation, and the public’s trust in scientific oversight. By circumventing established FDA approval processes through “enforcement discretion,” the policy introduces a precedent that could profoundly alter how medications are introduced and accessed in the United States.
Firstly, this move bypasses the rigorous scientific scrutiny—including human clinical trials for efficacy against placebos and long-term safety assessments for adverse effects like cancer or birth defects—that forms the bedrock of modern drug safety. This could expose patients to compounds with unknown risks or unproven benefits, potentially leading to adverse health outcomes or deterring individuals from seeking therapies with demonstrated effectiveness. It places a greater burden of risk on consumers, who may interpret the policy as a tacit endorsement of safety, despite HHS’s clarification that it does not confer FDA approval or establish clinical effectiveness.
Secondly, the policy challenges the authority and independence of the FDA, an agency specifically tasked with protecting public health by ensuring the safety and efficacy of drugs. When HHS leadership overrides the scientific recommendations of its own drug regulatory body, it raises questions about the integrity of scientific review and the potential for political influence to impact critical health decisions. This could erode public confidence in federal health agencies and the regulatory framework designed to safeguard citizens.
Furthermore, the increased availability of these peptides via compounding pharmacies and telehealth companies could blur the lines between rigorously tested pharmaceuticals and substances with limited scientific evidence. This could foster an environment where “medical freedom” is prioritized over evidence-based medicine, potentially creating a two-tiered system of drug access where some treatments adhere to strict safety standards and others operate under less stringent oversight. For a public increasingly reliant on readily available health information, discerning the true scientific standing of such treatments becomes more challenging.
Finally, the policy’s stated aim to “confront the risks of black-market peptides” by bringing them into a regulated, albeit less stringent, domestic framework is a complex one. While it seeks to reduce some of the dangers associated with entirely unregulated foreign suppliers, it simultaneously legitimizes the use of compounds that lack comprehensive safety and efficacy data. This shift could inadvertently expand the market for these unproven treatments, leading more individuals to use them without a full understanding of the potential risks, fundamentally impacting the landscape of patient care and drug development for years to come.